Board Of Directors

Christy Oliger brings nearly 30 years of strategic and operational experience in the biopharmaceutical industry. She built her career at Schering Plough and Genentech where she held varied roles in commercial and business unit leadership, as well as global R&D portfolio and project management. Most recently, Christy served as Senior Vice President, Oncology Business Unit Head at Genentech managing a portfolio of 15 products and ~$13B US revenue. She has also been responsible for overseeing the successful launches of Ocrevus for Multiple Sclerosis, Hemlibra for Hemophilia and Evrysdi for Spinal Muscular Atrophy. Christy currently sits on the boards of Karyopharm Therapeutics, Reata Pharmaceuticals and Sierra Oncology. She completed her undergraduate work in Economics at University of California, Santa Barbara.

Philip Astley-Sparke is Chief Executive Officer and co-founder of Replimune and has served as a member of our Board since our formation in 2015. Previously he was the President and CEO of BioVex Inc, which developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Philip relocated the Company from the UK to the US in 2005 before Biovex was acquired by Amgen for up to $1bn in 2011. Subsequent to BioVex/Amgen, Philip was President at uniQure where he established their US infrastructure including the world’s largest gene therapy manufacturing facility and served as the Company’s Chairman from 2016 until June 2021. Philip also previously served as Chairman of the board of directors of Oxyrane Limited, a biotechnology company, from 2012 to 2020. Philip is currently a Venture Partner at Forbion Capital and serves on the board of Forbion European Acquisition Corp. Philip received a BSc in Cellular and Molecular Pathology from Bristol University UK, qualified as a Chartered Accountant with Arthur Andersen and was a healthcare investment banker with Robert Fleming / Chase H&Q.

Robert Coffin is Founder, President and Chief Research & Development Officer of Replimune. Previously he was Founder & CTO of BioVex Inc, a spin out from his research group at University College London in 1999. BioVex was acquired by Amgen in 2011 where Rob was VP Global Development until 2013, before co-founding Replimune in 2015. Rob was awarded a PhD in virology from Imperial College London prior to his move to University College London in 1991.

Sander is Managing Partner at Forbion. He co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion Capital Partners in 2006. in addition to his leading role in Forbion’s investment team and its portfolio, he is responsible for Fundraising, Investor- and Public Relations. Besides Replimune, he currently serves on the boards of Forbion’s portfolio companies New Amsterdam Pharma B.V., Azafaros B.V., NorthSea Therapeutics (Chair), Xention and Oxyrane. Sander was responsible for two of Forbion’s substantial exits: Dezima was acquired by Amgen in 2015 for up to USD 1.55 billion and Biovex was sold to Amgen in March of 2011 for up to USD 1 billion. In recent years Sander has also served on the boards of Ario Pharma, Pulmagen, Fovea (sold to Sanofi in 2009), uniQure (IPO on Nasdaq in 2014), Argenta (sold to Galapagos in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella (sold to Abiomed in 2005), Pieris (IPO on Nasdaq in 2015) and has acted as the Chairman of the Board of AMT (IPO on Euronext in 2007). Before co-founding Forbion, he was an Investment Director at ABN AMRO Capital Life Sciences. His other activities at ABN AMRO included buy-out/ growth equities at ABN AMRO Capital, Equity Capital Markets Syndications (HQ Amsterdam) and Financial Institutions Relationship Management Latin America (Regional Office Miami). Sander holds degrees in Business and Financial Economics from the Free University of Amsterdam and Business Administration from Nijenrode University, The Netherlands.

Hyam (“Hy”) Levitsky has served as President, Research and Development at Century Therapeutics, Inc. since May 2019. Previously, Hy served as Executive Vice President, Chief Scientific Officer of Juno Therapeutics from May 2015 through April 2018. Prior to joining Juno, Hy held the position of Head of Cancer Immunology at Roche Pharma. Prior to that, Hy served as a Professor of Oncology, Medicine and Urology at The Johns Hopkins University School of Medicine. Hy received a B.S. from the University of Pennsylvania School of Engineering and Applied Science and an M.D. from The Johns Hopkins School of Medicine. His areas of expertise include Oncology, Immunology, Hematologic Malignances / Bone Marrow Transplantation (serving as Scientific Director of the George Santos Bone Marrow Transplant Program), Cellular and Molecular Medicine, and Pathobiology. Hy is also a founding Executive Committee member of the Cancer Immunotherapy Consortium of the Cancer Research Institute. He was a founding member of MIATA (Minimal Information About T cell Assays), advises the FDA on cancer immunotherapy issues and serves on the External Scientific Advisory Board of the Pasteur Institute’s Center for Human Immunology.

From 1999 to 2008 Kapil Dhingra served at Hoffmann-La Roche, including as Vice President, Head, Oncology Disease Biology Leadership Team, and Head, Oncology Clinical Development. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. From 1989 to 1996, he was a faculty member at The University of Texas M.D. Anderson Cancer Center and during his industry career maintained active faculty appointments at Indiana University School of Medicine from 1997 to 1999, and at Memorial Sloan Kettering Cancer Center in New York from 2000 to 2008. Kapil is board-certified in Internal Medicine and Medical Oncology and is currently a member of Boards of Directors of LAVA Therapeutics B.V., Black Diamond Therapeutics, Inc., Median Technologies Inc., and Autolus Therapeutics plc. He is also a member of the NCI Experimental Therapeutics panel and a member of the New Drug Advisory Committee of the EORTC. He has previously served on the Boards of several successful biotech companies, including Exosome Diagnostics, Five Prime Therapeutics Inc., Advanced Accelerator Applications S.A., Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics which were all acquired by major pharmaceutical companies. Kapil founded KAPital Consulting, LLC, in 2008, a company dedicated to helping biotechnology, pharmaceutical and diagnostic companies realize the clinical and commercial advances in oncology.

Joseph Slattery has been a member of our Board since 2017 and previously served as our lead independent director from March 2019 until March 31, 2020. Joe currently serves on the boards of directors of Omega Alpha SPAC, Morphic Therapeutic, Inc. and CVRx Inc., and he previously served as a director of Baxano Surgical, Inc., Exosome Diagnostics, Inc. and Micromet, Inc. He previously served as executive vice president and CFO of TransEnterix, Inc. (now Asensus Surgical, Inc.), as executive vice president and CFO at Baxano Surgical Inc., and as CFO and senior vice president of finance and information systems of Digene Corp. Joseph earned his bachelor’s degree in accountancy from Bentley University and is a certified public accountant.

Dieter Weinand has been a member of our Board since June 2018 and Chairperson since April 2020. Dieter served as the Executive Vice President of Primary Care and a member of the Executive Committee at Sanofi. Before moving to Sanofi, Dieter was the President of The Pharmaceuticals Division and member of the Management Board at Bayer AG.  During an international career stretching back over 25 years, he has held various positions in commercial, operational and strategic areas of the pharmaceutical industry. These included responsibilities spanning various therapeutic areas and geographies for companies such as Pfizer, Bristol Myers Squibb or Otsuka. Dieter earned an MS in Pharmacology and Toxicology from Long Island University, New York, and a BA in biology from Concordia College, New York. Dieter was previously a member the board of directors of Bayer AG, from 2013 to 2014, and HealthPrize Technologies LLC, from 2014 to 2018. 

Paolo Pucci has been a member of our Board since April 2020. Most recently, Paolo served as the Chief Executive Officer of ArQule, Inc., a biopharmaceutical oncology company engaged in the research and development of targeted therapeutics that was acquired by Merck in January 2020. Prior to joining ArQule in 2008, Paolo worked at Bayer AG from 2001 to 2008, where he served in a number of leadership capacities including President of the Oncology & Global Specialty Medicines Business Units and was a member of the Bayer Pharmaceuticals Global Management Committee. Before Bayer, Paolo held positions of increasing responsibility with Eli Lilly and Company from 1991 to 2001, culminating with his appointment as Managing Director, Eli Lilly Sweden AB. Paolo earned an MS in economics and accounting from Università degli Study di Napoli Federico II and an MBA in marketing and finance from the University of Chicago. Paolo has previously served on the Boards of several successful biotech companies including ArQule, Inc., Algeta ASA, until it was acquired by Bayer AG, Dyax Inc., until it was acquired by Shire Plc, NewLink Genetics Inc. and Trillium Therapeutics Inc., until its acquisition by Pfizer Inc. He currently serves as a board member of West Pharmaceuticals Services, Inc. and Merus N.V.